Also known as: SII
Serum Institute of India — leading development of a vaccine targeting the Bundibugyo Ebola strain in response to a Democratic Republic of Congo outbreak.
Verbatim sentences from the source article.
The Standard
… Another candidate, ChAdOx1 Bundibugyo, developed by Oxford University and the Serum Institute of India, has also been prioritised for further development. …
Ebola science race: Vaccines and drugs tested against Bundibugyo virusCitizen Digital
… The two front-running candidate vaccines are one using the ChAdOx1 platform, being developed by the University of Oxford and the Serum Institute of India, and another being worked on by US pharma firm Moderna using mRNA technology. …
WHO pleads for more support to tackle Ebola outbreakCapital News
… Leading candidates include vaccine programs developed by the University of Oxford in partnership with the Serum Institute of India, as well as mRNA-based vaccines from Moderna. …
US Sends Experimental Ebola Drug to Support Clinical Trials in DR CongoCitizen Digital
… The first to reach testing is likely one developed by Oxford and the Serum Institute of India, alongside another from U.S. …
US provides Ebola treatment for outbreak in Congo, bringing trials closerCitizen Digital
… The first to reach testing is likely one developed by Oxford and the Serum Institute of India, alongside another from U.S. …
US provides Ebola treatment for outbreak in Congo, bringing trials closerThe Standard
… It is being developed by the University of Oxford along with the Serum Institute of India, the world's largest vaccine maker. …
The vaccines and treatments being developed for Ebola outbreakCapital News
June 14 – India has emerged as a key player in global efforts to contain a deadly Ebola outbreak that has gripped parts of Central Africa, with the Serum Institute of India (SII) leading the development of a vaccine targeting the Bundibugyo strain of the virus. …
India Steps Up Ebola Vaccine Effort as Central Africa Battles Deadly OutbreakCitizen Digital
… This viral vector jab -- which will be manufactured by the huge Serum Institute of India -- could become available for clinical trials within two to three months, the WHO said. …
'We need to act now': Race to develop Ebola vaccine heats upThe Standard
… Another promising candidate is the ChAdOx1 Bundibugyo vaccine developed by Oxford University and the Serum Institute of India, which experts said could be ready for trials within two to three months. …
WHO recommends trial use of two vaccines as virus spreadsCapital News
… The Serum Institute of India is lined up to mass produce the Ebola vaccine once Oxford can supply medical-grade material. …
UK scientists developing Ebola vaccine that could be ready for trials in monthsThe Democratic Republic of Congo is fighting its worst Bundibugyo Ebola outbreak as scientists test multiple vaccines and treatments. Over 250 people have enrolled in a trial of obeldesivir, an experimental oral antiviral by Gilead Sciences, to prevent Ebola after exposure, while another WHO-sponsored trial evaluates monoclonal antibodies and antivirals in infected patients.
6 October 2026 · The Standard →
The Democratic Republic of Congo is fighting its worst Bundibugyo Ebola outbreak as scientists test multiple vaccines and treatments. Over 250 people have enrolled in a trial of obeldesivir, an experimental oral antiviral by Gilead Sciences, to prevent Ebola after exposure, while another WHO-sponsored trial evaluates monoclonal antibodies and antivirals in infected patients.
6 October 2026 · The Standard →
The World Health Organization called for more financial and other resources to combat the Ebola outbreak in the Democratic Republic of Congo, which it described as the biggest ever to have hit the DRC and is still expanding beyond the capacity of response efforts. There have been 3,802 confirmed cases with 1,707 deaths, according to WHO figures.
5 August 2026 · Citizen Digital →
The United States has provided doses of an experimental antibody drug developed by Mapp Biopharmaceutical to support clinical trials in the Democratic Republic of Congo's Ebola outbreak, marking a shift from prior US-only availability. The move comes as health authorities work to contain a rapidly spreading Bundibugyo strain outbreak that has recorded more than 1,000 cases and over 250 deaths.
24 June 2026 · Capital News →
The U.S. has provided doses of an experimental antibody drug from Mapp Biopharmaceutical for clinical trials in the Democratic Republic of Congo's Bundibugyo Ebola outbreak, which has caused over 1,000 cases and more than 250 deaths. The trial data could inform future U.S. regulatory review and potential approval.
24 June 2026 · Citizen Digital →
The U.S. has provided doses of an experimental antibody drug from Mapp Biopharmaceutical for use in clinical trials and compassionate use to fight an Ebola outbreak in Democratic Republic of Congo. The Bundibugyo strain has caused more than 1,000 cases in Congo and more than 250 deaths, with a handful of cases also reported in Uganda.
24 June 2026 · Citizen Digital →
More than 875 cases of the Bundibugyo Ebola strain have been confirmed, including 202 deaths, in a little over a month across DR Congo and Uganda, with no currently available vaccines or treatments for this strain. Scientists and pharmaceutical companies are racing to develop new vaccines and treatments, with the WHO calling an rVSV-based vaccine candidate "most promising" and estimating it will take seven to nine months before human testing can begin.
18 June 2026 · The Standard →
The Serum Institute of India is leading development of a vaccine targeting the Bundibugyo strain of Ebola in response to an outbreak in the Democratic Republic of Congo first reported in May 2026, which the WHO has declared a Public Health Emergency of International Concern. The vaccine, developed with the University of Oxford and CEPI, uses the same viral vector technology as the Oxford-AstraZeneca COVID-19 vaccine and trial doses are expected in the coming months.
14 June 2026 · Capital News →
Non-profit organisations announced Monday they are ramping up efforts to develop a vaccine for the Bundibugyo strain of Ebola, which has caused an outbreak in the Democratic Republic of Congo and Uganda with nearly 250 suspected deaths and more than 1,100 infections. The strain, for which there are no approved vaccines or treatments, has prompted a race to rapidly develop, manufacture and test a vaccine in clinical trials in the affected region.
1 June 2026 · Citizen Digital →
The World Health Organization has identified two candidate vaccines—rVSV Bundibugyo and ChAdOx1 Bundibugyo—and several treatment options for clinical trial evaluation as the Bundibugyo virus outbreak spreads in the Democratic Republic of Congo and Uganda. The rVSV vaccine could be ready for efficacy testing in seven to nine months, while the ChAdOx1 vaccine could be ready within two to three months.
30 May 2026 · The Standard →
Oxford University scientists are developing a new Bundibugyo Ebola vaccine that could be ready for clinical trials within two to three months, using ChAdOx1 technology developed during the Covid pandemic. The Democratic Republic of Congo outbreak has resulted in 750 suspected cases and 177 deaths, prompting the WHO to upgrade the risk from "high" to "very high."
22 May 2026 · Capital News →